
Biotech Business - January 27, 2025
FDA approves IV maintenance dosing of Leqembi for treatment of early Alzheimer’s in the US
The U.S. Food and Drug Administration (FDA) has approved BioArctic’s partner Eisai’s Supplemental Biologics License Application (sBLA) for Leqembi as a once every four weeks intravenous (IV) maintenance dosing.

Biotech Business - January 22, 2025
South Korea to grant precision medicine patent to Diamyd Medical
The South Korean Patent Office will grant a patent protecting the use of insulin-based antigens for the treatment of autoimmune diabetes in patients with the HLA DR4-DQ8 genetic marker.

Biotech article - January 21, 2025
First Danish patients treated with gene therapy for haemophilia B
CSL Behring Denmark has announced that the first Danish patients with haemophilia B were treated with the gene therapy HEMGENIX (etranacogene dezaparvovec).

Biotech Business - January 15, 2025
NOK 50 million to new Norwegian ATMP infrastructure
The Research Council of Norway has granted NOK 50 million to the Oslo University Hospital (OUH), in partnership with the University of Oslo and the Haukeland University Hospital (HUH) for the development and distribution of ATMPs, reports Sofia Lindén/Oslo Cancer Cluster (OCC).

Agreement - January 14, 2025
Synthego signs strategic licensing agreement with AstraZeneca
This agreement grants Synthego a global license to manufacture and distribute AstraZeneca's novel CRISPR gene editing enzyme, eSpOT-ON, recently published as engineered ePsCas9, to the worldwide research community.

Biotech Business - January 14, 2025
FDA accepts BioArctic’s partner Eisai’s BLA for subcutaneous maintenance dosing of Leqembi in the US
The U.S. Food and Drug Administration (FDA) has accepted BioArctic’s partner Eisai’s Biologics License Application (BLA) for Leqembi subcutaneous autoinjector (SC-AI) for weekly maintenance dosing.